Business Context and Reporting Period
This Form 8-K filing by Karyopharm Therapeutics Inc. reports on events occurring on February 15, 2019. The filing details the approval of equity awards and compensation adjustments for key executive officers by the Compensation Committee and the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and equity grants.
- Option Exercise Price: $9.21 per share (fair market value on February 15, 2019).
- Equity Grants: Options and Restricted Stock Units (RSUs) granted under the 2013 Stock Incentive Plan.
Material Changes and Compensation Details
The primary material change involves the approval of new equity awards and salary adjustments effective January 1, 2019, and February 15, 2019.
Equity Awards Granted (Effective Feb 15, 2019)
| Officer | Stock Options | RSUs |
|---|---|---|
| Michael G. Kauffman (CEO) | 231,200 | 87,200 |
| Sharon Shacham (President & CSO) | 231,200 | 87,200 |
| Christopher B. Primiano (EVP/CBO) | 102,800 | 38,700 |
| Cameron Peters (VP Finance) | 17,000 | 8,500 |
Vesting Schedule: Options vest 25% on the first anniversary, with the remainder vesting over 36 months. RSUs vest 25% annually over four years.
Cash Compensation Adjustments
| Officer | 2018 Bonus | 2019 Annual Salary | 2019 Target Bonus % |
|---|---|---|---|
| Michael G. Kauffman | $268,625* | $566,500 | 60% |
| Sharon Shacham | $183,063* | $468,500 | 50% |
| Christopher B. Primiano | $204,020 | $418,200 | 40% |
| Cameron Peters | $89,663 | $278,100 | 30% |
* Bonuses for Drs. Kauffman and Shacham were voluntarily reduced by $148,000 and $101,000, respectively, to offset cash bonuses paid to other employees in August 2018 for contributions to the first New Drug Application (NDA) submission.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of risks and contingencies beyond the standard disclosure of equity vesting terms. The mention of the NDA submission indicates ongoing clinical development progress.
Key Facts for Investor Verification
- Verify the dilution impact of the 688,100 total options and 221,600 RSUs granted to executives.
- Confirm the company's cash position to ensure it can fund the increased 2019 salary obligations and potential bonus payouts.
- Monitor the status of the New Drug Application (NDA) referenced in the bonus reduction footnote, as this is a critical milestone for the company.
- Review the 2013 Stock Incentive Plan to understand remaining share availability for future grants.